/Join_Us.gif)
/Morrison_and_Foerster_with_frame.png)
/Danica_Pension_with_frame.png)
/MVA_Publications.gif)
/Clinical_trial_470_x_80_(new).gif)
Clinical Trials Update provides you with latest news about clinical trials conducted by MVA member companies. The update gives insight to progress in studies, results and possible indications.
Novo Nordisk discontinues phase 3 clinical trial with NovoSeven in trauma
11 June - Novo Nordisk today announced the decision to discontinue the phase 3 clinical trial with NovoSeven for the treatment of bleeding in patients with severe trauma. The decision was made based on the results of an analysis for futility conducted by the independent Data Monitoring Committee.
Ofatumumab in subcutaneous study in rheumatoid arthritis
10 June - Genmab has announced that the will initiate a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20) in rheumatoid arthritis patients, stable on methotrexate. Ofatumumab is an investigational drug being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and rheumatoid arthritis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.
Over 70% of patients reach target with NovoMix® 30 in largest ever diabetes study
9 June - New data from the IMPROVE study show that significant improvements in glycaemic (blood sugar) control can be achieved with premixed modern insulin, NovoMix 30, in patients poorly controlled on other, or no previous pharmaceutical treatment. The results were announced over the weekend at the 68th annual meeting of the American Diabetes Association in San Francisco.
Clinical study shows liraglutide reduced blood sugar, weight and blood pressure in patients with type 2 diabetes
9 June - Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride. Data presented over the weekend at the 68th Scientific Sessions of the American Diabetes Association demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral antidiabetic drug.
Bavarian Nordic enters clinical trials with prostate cancer vaccine
3 June - Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during second half year 2009.
